Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety and Efficacy of Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Patients With Relapsed or Refractory B-cell Lymphoma: An Open-label, Single-arm Clinical Study

Next Previous
Trial Profile

The Safety and Efficacy of Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Patients With Relapsed or Refractory B-cell Lymphoma: An Open-label, Single-arm Clinical Study

Status: Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 24 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD19/CD22-targeting-T-cell-therapy-Eureka-Therapeutics (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
  • Indications B-cell lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 24 Sep 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top